Obe-cel in Refractory Progressive Forms of Multiple Sclerosis

The main purpose of this study is to evaluate if obe-cel is safe or causes any side effects in adults with refractory progressive MS. The study also plans to assess if obe-cel can show early signs of efficacy in MS. The trial includes only 1 group of participants (single-arm). The study population comprises participants with progressive forms of MS, not responsive to highly effective therapies. Upon confirmation of study eligibility, participants will receive chemotherapy (used here for lymphodepletion) over 1 to 3 days in preparation for receiving a single obe-cel infusion. Participants will be checked closely in the 28 days following obe-cel treatment. After this, participants will be monitored to evaluate safety and efficacy up to 24 months.

NCT Number	NCT07139743
Lead Sponsor	Autolus Limited
Conditions	Progressive Multiple Sclerosis
Enrollment	18 participants
Start Date	2025-08-04
Primary Completion	2029-08-15 (estimated)
Study Completion	2029-08-15 (estimated)
Updated on ClinicalTrials.gov	2026-03-23